{"product_id":"tcrt-marketing-mix","title":"(TCRT) Alaunos Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alaunos Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing strategy, distribution channels, and promotional tactics to show how it competes in biotech\/therapeutics. The page includes a real preview\/sample of the analysis so you can assess style and content; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTCR Library, 10 receptors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc.’s core product is its TCR Library platform, which includes 10 T-cell receptors in clinical development for adoptive T-cell receptor engineered therapies. As of July 2026, it is the company’s main product asset and targets solid tumors with shared cancer mutations. The program is built to broaden treatment options in cancers where shared mutations can support a wider patient fit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I\/II clinical stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. lead product is still in Phase I\/II, so it is not a marketed therapy yet. The value proposition rests on early safety and efficacy signals, not sales, and the mix is still research-led rather than revenue-led. Commercial launch depends on clear clinical benefit, later-stage success, and FDA progress, with no approved product or product sales today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKRAS, TP53, EGFR targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc.’s library targets mutated KRAS, TP53, and EGFR, three drivers found across hard-to-treat tumors; KRAS mutations appear in about 25% of solid tumors, while TP53 is altered in roughly 50%. EGFR mutations are common in non-small cell lung cancer, at about 10% to 15% in Western patients. This patient-matched design makes the offer highly specialized and precision-oncology focused.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSolid tumors, 6 cancer types\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. positions Solid tumors, 6 cancer types as a multi-cancer therapeutic platform for non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers, all large solid-tumor markets with high unmet need. The six-indication reach gives it more than one development path, which can matter in a market where one program can fail fast.\u003c\/p\u003e\n\u003cp\u003eThe company’s broad setup supports a platform story, not a single-asset pitch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 target cancer types\u003c\/li\u003e\n\u003cli\u003eSolid-tumor focus\u003c\/li\u003e\n\u003cli\u003eHigh unmet medical need\u003c\/li\u003e\n\u003cli\u003eMultiple development paths\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ehunTR and mbIL-15 platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. is widening its mix beyond the TCR Library with hunTR and mbIL-15. hunTR targets human neoantigen T-cell receptors, while mbIL-15 is built to support solid tumor treatment, a space that represents about 90% of adult cancers. That gives Alaunos Therapeutics, Inc. 2 added programs, which lowers single-asset risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ehunTR: human neoantigen TCRs\u003c\/li\u003e\n\u003cli\u003embIL-15: solid tumor support\u003c\/li\u003e\n\u003cli\u003eBroader pipeline, less concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlaunos’ 10-TCR Pipeline Spans 6 Cancers, With No Sales Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. product mix is led by its TCR Library, a Phase I\/II adoptive T-cell receptor platform with 10 TCRs across 6 solid-tumor types. It targets KRAS, TP53, and EGFR, with no approved product or sales yet. hunTR and mbIL-15 add 2 more pipeline assets and reduce single-asset risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead product\u003c\/td\u003e\n\u003ctd\u003eTCR Library\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical assets\u003c\/td\u003e\n\u003ctd\u003e10 TCRs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget cancers\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdded programs\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, company-specific 4P analysis of Alaunos Therapeutics, Inc.’s product, pricing, place, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Alaunos Therapeutics’ 4Ps into a quick, decision-ready snapshot for fast strategic review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary industry reports, clinical trial databases, and regulatory filings to speed due diligence on Alaunos Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHouston, Texas HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics is headquartered in Houston, Texas, which anchors its corporate and strategic base. The site supports management, business development, and partner coordination, so key decisions stay close to the company’s central operations. Houston’s metro area has more than 7 million people, giving the Company access to a deep talent and partner pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. uses clinical trial sites as its only real “place” channel, so patients get access through enrollment at oncology research centers rather than retail or hospital pharmacy sales. For a pre-commercial biotech with no commercial distribution network, this keeps reach narrow and limited to trial settings where investigators can administer investigational cell therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMD Anderson partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. works with The University of Texas MD Anderson Cancer Center, ranked No. 1 for cancer care in U.S. News \u0026amp; World Report 2025-26. This puts part of the work inside a top oncology research hub, which supports translational research and clinical development. It also links Alaunos to deep cancer trial infrastructure and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNCI agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. uses National Cancer Institute agreements to widen its R\u0026amp;D reach beyond its own lab base. The company has both a patent license and an R\u0026amp;D agreement with NCI, which gives it access to federal research know-how and protected IP. This is a key non-commercial channel for scientific exchange and asset access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent access and shared research\u003c\/li\u003e\n\u003cli\u003eLinks to federal cancer networks\u003c\/li\u003e\n\u003cli\u003eSupports IP and know-how flow\u003c\/li\u003e\n\u003cli\u003eStrengthens early-stage development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePGEN licensing agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. keeps a licensing agreement with PGEN Therapeutics, Inc., which gives it access to outside technology and development rights. For a clinical-stage Company Name, that matters because it can source product candidates without building every asset from scratch. In its latest public filings, Alaunos reported $0 product revenue, so licensed programs remain central to its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to PGEN technology\u003c\/li\u003e\n\u003cli\u003eSupports external development rights\u003c\/li\u003e\n\u003cli\u003eFits a clinical-stage model\u003c\/li\u003e\n\u003cli\u003e$0 product revenue reported\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlaunos’ Access Runs Through Clinical Trial Sites, Not Retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. has no retail or hospital distribution; its Place is clinical trial sites, so patient access runs through oncology research centers. Its Houston, Texas base supports management and partner coordination, while MD Anderson and NCI ties anchor research access. That fits a pre-commercial model with $0 product revenue reported.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace channel\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003ctd\u003eOnly access route\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHouston HQ\u003c\/td\u003e\n\u003ctd\u003e7M+ metro area\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial revenue\u003c\/td\u003e\n\u003ctd\u003e$0 product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAlaunos Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Alaunos Therapeutics, Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, fully editable marketing mix analysis you'll download immediately after checkout, covering product, price, place, and promotion tailored to Alaunos.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact, final version of the analysis—comprehensive, actionable, and ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSEC filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. promotes itself mainly through SEC filings, a standard channel for public biotechs with no product revenue. These reports spell out pipeline progress, risks, and corporate updates, and they also show the company’s cash position and losses as investors track dilution and runway. For a pre-revenue biotech, the filing cadence itself is part of the marketing mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. uses press releases to share trial updates, collaborations, and corporate actions, and that matters because a clinical-stage oncology company lives on news flow. These releases build awareness with investors and scientific stakeholders, while also reinforcing credibility around pipeline progress and study milestones. For a company with no marketed cancer product, each update can move attention faster than ads or broad brand campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. uses 3 scientific collaborations—MD Anderson, NCI, and PGEN—as promotion by third-party validation, not just advertising. These names signal that outside institutions see enough value in the platform to work with it. In biotech, that kind of partner support often matters more than paid brand spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhase I\/II trial activity is Alaunos Therapeutics, Inc.’s main promotion engine because it generates clinical evidence before any saleable product. In biotech, each enrolled patient, data readout, and safety update can be shared publicly, which raises visibility with physicians, investigators, and patients.\u003c\/p\u003e\n\u003cp\u003eThat matters because early-stage trial milestones are the proof points investors and partners track; for a small-cap biotech with no commercial revenue, clinical progress is the message. The company can use enrollment, dose-escalation, and readout updates to keep attention on its pipeline and support trial recruitment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I\/II trials create public milestones.\u003c\/li\u003e\n\u003cli\u003eClinical updates raise physician awareness.\u003c\/li\u003e\n\u003cli\u003eEnrollment helps attract investigators and patients.\u003c\/li\u003e\n\u003cli\u003ePromotion is evidence-led, not ad-led.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormer ZIOPHARM name change\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics adopted its current name in January 2022, replacing ZIOPHARM to signal a new strategic identity and reset how the market views the business. For promotion, the name change supports repositioning with investors and partners by tying the brand to its cell-therapy focus. It is a simple corporate messaging move, but it helps separate the new story from the former ZIOPHARM legacy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJanuary 2022 rebrand\u003c\/li\u003e\n\u003cli\u003eSignals strategic repositioning\u003c\/li\u003e\n\u003cli\u003eSupports investor messaging\u003c\/li\u003e\n\u003cli\u003ePart of corporate promotion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlaunos Sells the Story Through Trials, Not Ads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. promotes through SEC filings, press releases, and trial milestones, not paid ads. With no product revenue, its main message is pipeline progress, cash runway, and study updates. Third-party ties with MD Anderson, NCI, and PGEN add credibility, and the January 2022 name change helped reset the market story.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion channel\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC filings\u003c\/td\u003e\n\u003ctd\u003eOngoing public disclosure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePress releases\u003c\/td\u003e\n\u003ctd\u003eTrial, collaboration, and corporate updates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific partners\u003c\/td\u003e\n\u003ctd\u003eMD Anderson, NCI, PGEN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebrand\u003c\/td\u003e\n\u003ctd\u003eName changed in January 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed product price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. had 0 approved commercial products as of July 2026, so there is no public customer price for any therapy. Any future pricing will depend on FDA approval, payer coverage, and reimbursement terms. For now, the market measures value through clinical milestones and pipeline progress, not list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial-stage economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. has no product sales, so its price story is tied to research funding and trial spend, not end-user pricing. In the latest filing cycle, the Company reported $0 product revenue, which is normal for a clinical-stage biotech and shows why capital raises fund operations. This makes the business model investment dependent, with pricing shaped by financing needs and dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing terms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. faces price exposure mainly through licensing terms, not consumer pricing. In biotech deals, access to outside technology is often paid with upfront fees, milestone payments, and sometimes royalties, so the cash cost depends on the contract. For a development-stage company, this can directly affect burn rate and future dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture reimbursement unknown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. has no approved oncology product, so future reimbursement and net price are still unknown. If a therapy reaches market, payers will likely demand clear clinical benefit, since high-value cancer drugs often need strong outcomes data to win coverage and support premium pricing.\u003c\/p\u003e\n\u003cp\u003eReimbursement will be a key driver of any eventual net price, but that stage has not been reached yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved product, no set reimbursement\u003c\/li\u003e\n\u003cli\u003ePayer acceptance will shape net price\u003c\/li\u003e\n\u003cli\u003eStrong outcomes data will matter most\u003c\/li\u003e\n\u003cli\u003eCommercial pricing remains unpriced risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo discount or retail model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. has no retail discounting, subscriptions, or direct-to-consumer price list because its cell therapies are investigational and only supplied in clinical trials. There is no commercial price architecture yet, so pricing becomes relevant only after FDA approval and launch. Its latest public filings show it is still in a development stage, not a sales stage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial-only supply, no retail pricing\u003c\/li\u003e\n\u003cli\u003eNo discounts or subscriptions\u003c\/li\u003e\n\u003cli\u003ePrice model waits for approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlaunos Has No Approved Product, So Pricing Remains Unset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlaunos Therapeutics, Inc. still has no approved product as of FY2026, so there is no commercial price or reimbursement rate to measure. In FY2025\/FY2026 filings, product revenue stayed at $0, which means price is still an R\u0026amp;D and financing issue, not a sales issue. Any future net price will depend on FDA approval, payer coverage, and trial data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003eFY2025\/FY2026\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved commercial products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent pricing status\u003c\/td\u003e\n\u003ctd\u003eNot set\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235108069641,"sku":"tcrt-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tcrt-marketing-mix.webp?v=1785733274","url":"https:\/\/dcfanalyst.com\/products\/tcrt-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}